Home NDC 0003-0898-28 ELIQUIS SPRINKLE
Product NDC 0003-0898
Requested package NDC 0003-0898-28
11-digit product format 000030898
Labeler code 0003
Product ID 0003-0898_188961fc-00f8-4848-a611-c3c85764baf8
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name apixaban
Dosage form CAPSULE
Route ORAL
Labeler E.R. Squibb & Sons, L.L.C.
Application NDA220073
Marketing category NDA
Marketing start 2025-09-15
Substance APIXABAN
Active strength .15 mg/1
Pharmacologic classes Factor Xa Inhibitor [EPC], Factor Xa Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 45 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N220073-001 ELIQUIS SPRINKLE APIXABAN 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17
Orange Book patents# Current patent rows page 1 of 1 · 4 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 N220073-001 6967208*PED 2027-05-21 Pediatric extension N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 N220073-001 11896586*PED 2041-05-22 Pediatric extension
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 2 matching rows.
Application-product, Exclusivity code, Expiration table Application-product Exclusivity code Expiration N220073-001 NP 2028-04-17 N220073-001 PED 2028-10-17
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-11-14 07:37:17 2026-10 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 c2088c7a36db…2026-09-14 22:38:34 2026-08 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 84e616aacf4f…2026-08-18 06:07:40 2026-07 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 6a471c1ec25d…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 ELIQUIS SPRINKLE 0.15MG FOR SUSPENSION / ORAL RLD, RS 2025-04-17 a50c72e98297…
Observed Orange Book patent history# Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-11-14 07:37:17 2026-10 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220073-001 6967208*PED 2027-05-21 Pediatric extension d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 d4dbc9d85df4…2026-11-14 07:37:17 2026-10 N220073-001 11896586*PED 2041-05-22 Pediatric extension d4dbc9d85df4…2026-10-15 13:18:30 2026-09 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220073-001 6967208*PED 2027-05-21 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 c2088c7a36db…2026-10-15 13:18:30 2026-09 N220073-001 11896586*PED 2041-05-22 Pediatric extension c2088c7a36db…2026-09-14 22:38:34 2026-08 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220073-001 6967208*PED 2027-05-21 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N220073-001 11896586*PED 2041-05-22 Pediatric extension 84e616aacf4f…2026-08-18 06:07:40 2026-07 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N220073-001 6967208*PED 2027-05-21 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N220073-001 11896586*PED 2041-05-22 Pediatric extension caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N220073-001 6967208*PED 2027-05-21 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N220073-001 11896586*PED 2041-05-22 Pediatric extension 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 6967208*PED 2027-05-21 Pediatric extension 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N220073-001 11896586*PED 2041-05-22 Pediatric extension 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N220073-001 6967208*PED 2027-05-21 Pediatric extension 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N220073-001 11896586*PED 2041-05-22 Pediatric extension 6a471c1ec25d…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 6967208 2026-11-21 U-4180 Drug substance, Drug product 2025-05-16 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 6967208*PED 2027-05-21 Pediatric extension a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 11896586 2040-11-22 U-4180 Drug product 2025-05-16 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N220073-001 11896586*PED 2041-05-22 Pediatric extension a50c72e98297…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base ELIQUIS SPRINKLE
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength APIXABAN .15 mg/1
Harmonized UNII identifiers# UNII identifiers page 1 of 1 · 1 matching rows.
Identifier, FDA.report destination table Identifier FDA.report destination 3Z9Y7UWC1J Internal UNII lookup
Harmonized SPL set identifiers# SPL set identifiers page 1 of 1 · 1 matching rows.
DailyMed Product Concepts# DailyMed Socrata Ingredients# Ingredient, Type, UNII table Ingredient Type UNII DailyMed label SPL version Uploaded apixaban ACTIVE INGREDIENT 3Z9Y7UWC1J ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 apixaban ACTIVE MOIETY 3Z9Y7UWC1J ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 anhydrous lactose INACTIVE INGREDIENT 3SY5LH9PMK ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 cellulose, microcrystalline INACTIVE INGREDIENT OP1R32D61U ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 croscarmellose sodium INACTIVE INGREDIENT M28OL1HH48 ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 ferric oxide red INACTIVE INGREDIENT 1K09F3G675 ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 ferric oxide yellow INACTIVE INGREDIENT EX438O2MRT ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 hypromelloses INACTIVE INGREDIENT 3NXW29V3WO ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 lactose monohydrate INACTIVE INGREDIENT EWQ57Q8I5X ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 magnesium stearate INACTIVE INGREDIENT 70097M6I30 ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 sodium lauryl sulfate INACTIVE INGREDIENT 368GB5141J ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 titanium dioxide INACTIVE INGREDIENT 15FIX9V2JP ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7 triacetin INACTIVE INGREDIENT XHX3C3X673 ELIQUIS (APIXABAN) TABLET, FILM COATED [E.R. SQUIBB & SONS, L.L.C.] 7
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 0003-0898-28 00003089828 28 CAPSULE in 1 BOTTLE (0003-0898-28) 28 capsule 2025-09-15 No No Current